Since the March sell-off, LJPC's stock had mostly languished in spite of positive analysts' recommendations. However, by the end of 2014, the stock began a rally that has led to all-time highs in 2015. This article will provide the uninitiated …
SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (OTCBB:LJPC), a biopharmaceutical company dedicated to improving and preserving human life by acquiring and developing innovative pharmaceutical products, …
La Jolla Pharmaceutical Co. (NASDAQ: LJPC) has seen its shares jump on this wave with an ... in a 52-week trading range of $6.17 to $24.89. The stock has a consensus analyst price target of $36.20.
After announcing that its phase 3 ATHOS-3 study would be published in a prestigious medical journal, clinical-stage biotech La Jolla Pharmaceutical (NASDAQ: LJPC) saw its shares ... David and Tom Gardner have a stock tip, it can …
Perceptive Advisers reported another $21 million buying (700k shares) in La Jolla Pharmaceuticals (LJPC) stock today (which appears to be bought in the recent $100M offering), thus increasing its stake to 4.3 million shares. The recent …
La Jolla Pharmaceutical Company (LJPC) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock. And for technical investors there is some hope when looking at LJPC given that, …
La Jolla Pharmaceutical Company (NASDAQ: LJPC) announced that it has called a ... available for distribution to holders of the approximately 66M shares of common stock issued and outstanding.
LJPC closed Thursday's trading at $28.65 ... Ritter Pharmaceuticals Inc. (RTTR) is all set to implement a 1-for-10 reverse split of its Common Stock, par value $0.001 per share, which will come into effect on March 23, 2018. As a result of the …
LJPC) has been on a tear over the past year. Now it is looking to capitalize on its increased price and raise more capital. The company announced the pricing of an underwritten offering of 2.55 million shares of its common stock at $38.00 per …